Compare CBLL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBLL | GERN |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.1M | 753.3M |
| IPO Year | 2024 | 1996 |
| Metric | CBLL | GERN |
|---|---|---|
| Price | $22.41 | $1.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $24.67 | $3.00 |
| AVG Volume (30 Days) | 553.7K | ★ 6.8M |
| Earning Date | 02-24-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $82,813,000.00 | ★ $183,403,000.00 |
| Revenue This Year | $37.43 | $147.42 |
| Revenue Next Year | $27.73 | $39.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 37.93 | ★ 522.13 |
| 52 Week Low | $10.01 | $1.04 |
| 52 Week High | $26.04 | $3.59 |
| Indicator | CBLL | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 69.81 | 56.51 |
| Support Level | $20.39 | $1.30 |
| Resistance Level | $22.96 | $1.37 |
| Average True Range (ATR) | 0.97 | 0.06 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 79.57 | 39.93 |
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.